Media stories about Avenue Theraptc (NASDAQ:ATXI) have been trending positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Avenue Theraptc earned a daily sentiment score of 0.30 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.5008327667661 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Shares of Avenue Theraptc (NASDAQ ATXI) traded down 1.95% on Friday, reaching $6.55. The company’s stock had a trading volume of 16,013 shares. Avenue Theraptc has a 1-year low of $5.94 and a 1-year high of $20.53. The stock’s market capitalization is $21.88 million. The stock has a 50-day moving average of $7.83 and a 200 day moving average of $7.84.

ILLEGAL ACTIVITY NOTICE: “Avenue Theraptc (ATXI) Given News Sentiment Rating of 0.30” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at

Avenue Theraptc Company Profile

Avenue Therapeutics, Inc is a pharmaceutical company. The Company is engaged in acquiring, licensing, developing and commercializing products principally for use in the acute or intensive care hospital setting. Its product candidate is intravenous (IV) Tramadol, an intravenous formulation of tramadol hydrochloride (HCl), for the management of moderate to moderately severe postoperative pain.

Receive News & Ratings for Avenue Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Theraptc and related companies with's FREE daily email newsletter.